Phase 2 trial finds mezagitamab increases platelet counts in adults with persistent or chronic ITP
Mezagitamab increased platelet counts in adults with chronic or persistent immune thrombocytopenia in this early trial
A multicenter, double-blind, randomized, placebo-controlled Phase 2 trial in 41 adults with persistent or chronic ITP found 91% of participa…
Mezagitamab helped 91% of adults with chronic low platelet counts reach target levels, while only 23% on placebo did so in this early trial.
N-acetylcysteine protocol study for early-onset preeclampsia progression in Lagos, Nigeria
NAC study protocol for early-onset preeclampsia in Lagos hospitals planned for 2026 to 2028
This study protocol outlines a planned proof-of-concept trial evaluating daily oral N-acetylcysteine versus placebo in sexually active women…
A planned 2026 trial in Lagos hospitals will test if a daily antioxidant tablet slows the progression of early-onset preeclampsia in pregnan…
Hydroxychloroquine did not prevent SLE progression in incomplete lupus patients in randomized trial
Hydroxychloroquine did not slow disease progression in incomplete lupus patients over two years
A randomized, double-blind trial of 180 patients with incomplete lupus erythematosus found hydroxychloroquine did not reduce progression to …
Hydroxychloroquine failed to slow lupus progression in patients with early symptoms over two years, matching placebo results.